Objective-The objective of this study was to measure the role of platelets and red blood cells on thrombus propagation in an in vitro model of venous valvular stasis. Approach and Results-A microfluidic model with dimensional similarity to human venous valves consists of a sinus distal to a sudden expansion, where for sufficiently high Reynolds numbers, 2 countercurrent vortices arise because of flow separation. The primary vortex is defined by the points of flow separation and reattachment. A secondary vortex forms in the deepest recess of the valve pocket characterized by low shear rates. An initial fibrin gel formed within the secondary vortex of a tissue factor-coated valve sinus. Platelets accumulated at the interface of the fibrin gel and the primary vortex.
T he initiation and propagation of venous thrombosis (VT) are poorly characterized compared with arterial thrombosis. 1 This is due, in part, to the lack of animal and in vitro models that replicate the hemodynamics and microenvironment of venous valves where most VT in humans originates. The most common animal models of VT are initiated via partial or total ligation of vessels like the inferior vena cava that do not have valves. 2, 3 In vitro flow chambers are often used to simulate the flows and forces that regulate thrombus formation in straight or stenotic channels, but few recreate the geometry of venous valves. [4] [5] [6] In this study, we describe a scaled model of human venous valves that recreates their essential hemodynamics to determine the influence of blood flow, red blood cells (RBC), and platelets on thrombus propagation initiated by immobilized TF (tissue factor).
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VT is thought to result from a combination of flow stasis, hypoxia-induced activation of the endothelium, and subsequent accumulation of procoagulant factors in the valve sinus. 7, 8 Flow stasis broadly refers to a complete lack of blood flow but also disturbed flows that result in low flow niches. Venous valve stasis caused by aging and immobility reduces blood flow into and within the valve sinus. 9 These unusual hemodynamic conditions in the valve sinus yield a hypoxic environment that results in the presentation of P-and E-selectin and von Willebrand factor on endothelial cells, 10 which in turn supports adhesion of blood cells and microparticles. 11 Accumulation of TF-positive microparticles, monocytes, and platelets initiates coagulation through the extrinsic pathway. 1 The intrinsic pathway may also play a role in thrombus propagation via exposure of neutrophil extracellular traps. 11 Computational models of VT suggest that a threshold quantity of TF must accumulate before the initiation of coagulation. 12 However, after this initiation, the biophysical mechanisms that regulate the propagation of a thrombus into the lumen of the vein are yet to be quantified.
The histology of venous thrombi implies a role for blood flow in thrombus propagation. The alternating layered structure of red, fibrin-rich regions that begin at the vessel wall in the valve sinus followed by white, platelet-rich regions suggests a mechanism of platelet accumulation to the initial fibrin-rich regions. 13 The geometry of the valve sinus defined by a large cavity distal to the expansion created by the valve leaflets yields unique flow patterns. Flow through fixed venous valves of dogs shows a large primary vortex adjacent to the valve cusps and a secondary vortex in the deepest recess of the valve pocket. 14 The fluid velocity in this secondary vortex is extremely slow and corresponds to the most hypoxic area of the valve sinus. 15 Vortical flows in the valve sinus have also been observed by ultrasound in human venous valves. 16 Vortical flows caused by flow separation downstream of a stenosis or sudden expansion support thrombus formation. 17 Blood cells that enter these flows have a long residence time that promotes platelet-platelet collisions and ultimately aggregation in sudden annular expansions. 18 RBC enhance the accumulation of platelets in vortical flows in a hematocrit (HCT)-dependent manner. 15, 18, 19 The low wall shear rates in vortical flows support platelet adhesion to collagen and neutrophil adhesion to P-selectin, with the most accumulation occurring near reattachment points in sudden annular expansions and backwards facing steps. 18, 20, 21 These geometries are relevant to arterial thrombosis or vascular injuries where collagen is exposed to flowing blood; however, they do not incorporate TF-dependent coagulation or fibrin deposition, which are central to the pathophysiology of VT.
In this study, we present TF-initiated thrombus propagation in a model venous valve. We use scaling arguments to fabricate valve geometries that have geometric similarity to human valves. A sudden expansion geometry with undercuts of different angles results in primary and secondary vortices at sufficiently high flow rates. An initial fibrin-rich thrombus forms in the secondary vortex; however, RBC and platelets within the primary vortex are necessary to propagate the thrombus.
Materials and Methods

Materials
Materials are available in the online-only Data Supplement.
Computational Fluid Mechanics
Flow through the model venous valve was simulated at steady state for the 90°, 120°, 135°, and 150° angles using the same dimensions as the device using computational fluid dynamics software (COMSOL Multiphysics, COMSOL Inc, Burlington, MA). The entrance condition was set as a constant flow rate to match the Reynolds number, Re, for a Newtonian fluid with a viscosity of 3.5 cP. The outlet condition was set as a zero pressure. The other boundary conditions were set to no-slip. The solution to the Navier-Stokes equation was calculated at a finer mesh size (1 379 416 elements). The simulations were repeated at a fine (422 701 elements), normal (159 625 elements), and coarse (76 256 elements) mesh to insure grid independence ( Figure I in the online-only Data Supplement).
Re Matching
The Re is a nondimensional number that compares viscous to inertial forces in flow. It is given by
where ρ is the fluid density, μ the fluid viscosity, v the average velocity, and D is the characteristic dimension (the channel height in our case). When we increased the HCT, we increased the viscosity of the suspension. At the same flow rate, this would lead to a smaller Re. To achieve dynamic similarity and match Re across different HCT, we estimate the viscosity using
HCT where µ rel is the viscosity of the suspension relative to the suspending fluid viscosity, and HCT the hematocrit. 22 These flow rates are in Tables I and II in the online-only Data Supplement for plasma and buffer, respectively.
Microfluidic Devices
The flow chamber consists of 150 µm wide PDMS (polydimethylsiloxane) channels expanding into a 450-µm wide channels at angles 90°, 120°, 135°, or 150°, where larger angles represent a more severe undercut. A vacuum chamber surrounds the channels to aid in the removal of air bubbles. Fabrication details are found in the onlineonly Data Supplement.
Visualization of Streaklines
To measure streaklines, 3-µm fluorescein isothiocyanate-labeled polystyrene beads at a number density of 200 000/µL in HEPES-buffered saline (HBS) were mixed with washed RBC at HCT of 0, 0.2, 0.4, and 0.6. A 500-µL Hamilton Gastight syringe was filled with the suspension and connected to a microfludic device via 0.01″ ID tubing. Flows rates were set to match desired Re of 0.1, 10, and 25. Images were acquired with an inverted microscope (Olympus IX81, ×20 numerical aperture [NA]=0.45, excitation/emission [ex/em] 475/505 nm) at 100 ms exposure.
Blood Collection
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (University of Colorado, Boulder) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all subjects for being included in the study. Blood was collected from healthy donors by venipuncture into 4.5 mL vacutainer tubes containing 3.2% sodium citrate. The first tube of blood collected was treated as waste to eliminate any activated platelets because of venipuncture. Donors had not consumed alcohol within 48 hours before the draw nor had they taken any prescription or over-the-counter drugs within the previous 10 days excluding oral contraception.
Platelet-rich plasma (PRP) and packed RBC were obtained by centrifugation of citrated whole blood at 200g for 20 minutes. The top fraction above the buffy coat was collected for PRP, and platelet counts were measured by flow cytometry (EMD Millipore, guava easyCyte 6 2L, Hayward, CA) gated by size. 
Reconstituted Blood Rheology
Packed RBC (see above for centrifugation procedure) were added to autologous donor plasma or NPP to achieve an HCT of 0.4. The RBC suspension (17 mL) was introduced into the cup (diameter=30.02 mm; depth=78.01 mm) of the Peltier Concentric Cylinder system of the DH-3 rheometer, after which the bob (diameter=27.96 mm; depth=41.91 mm) was lowered into position with an operating gap of 5.91 mm, and temperature was maintained at 37°C. FC-40 oil (1 mL; viscosity=1.5 cSt) was carefully pipetted on top of the suspension to prevent aggregation at the air-liquid interface. The shear rate sweep from 0.1 to 1000/s was performed for 10 seconds at each shear rate to measure the shear-dependent viscosity of the RBC suspension blood. Measurements were taken every 5 minutes for 45 minutes in total. The viscosity of the autologous donor plasma and NPP were measured at 100/s to calculate the relative viscosity for each suspension.
Microfluidic Device Operation
Stock Innovin TF was diluted 1:9 in HBS and used to pattern the postexpansion half of the channel including the pockets by carefully backfilling via pipette aspiration. The device was connected to vacuum to ensure that there were no air bubbles in the valve pocket. After a 1-hour incubation of TF at room temperature, the small tubing, connector, and large tubing were connected as shown in Figure II in the onlineonly Data Supplement. A 60-mL syringe was filled with 2% BSA in HBS to the 25 mL mark, and a 3 mL syringe is filled with recalcification solution to the 3 mL mark. The 3 mL syringe is connected first to the calcium inlet, and recalcification buffer is perfused until it comes out of the blood inlet. Then the 60-mL syringe is connected. This order insures that the dead volume between the calcium inlet and the T-junction is filled with calcium buffer and not BSA solution. The syringes were placed onto a syringe pump (Harvard Apparatus PhD 2000), the flow rate set to match the desired Re (Table I in the onlineonly Data Supplement), and the solutions were perfused through the tubing for 5 minutes to insure a tight connection with the pump as well as to block the tubing along the path of blood flow. The tubing was then connected to the inlet of the microfluidic device, and an additional tubing (60 cm, 0.01″ tubing) containing HBS was connected to an outlet of the device. The whole system was perfused for 5 minutes and allowed to block with 2% BSA in HBS for an additional hour.
Reconstituted Blood Studies
When the plasma, RBC suspension, PRP, reconstituted blood, or whole blood was ready for perfusion, the 60-mL syringe was emptied of the blocking solution and filled with one of these solutions or suspensions to the same volume it held before removal to insure it will fit on the syringe pump without adjustments. Flow was started immediately. Images of the valve pocket were captured every 20 seconds in a confocal microscope (Olympus FV10i, ×60 objective NA=0.95) at 3 z-locations. Alternatively, for thrombus area assays, images were captured with an inverted microscope (Olympus IX81, ×20 NA=0.45, ex/em 475/505 nm, 545/580 nm) every 10 seconds.
Whole Blood and Platelet Inhibitor Studies
Citrated whole blood from one blood draw was separated into two 13 mL samples. The first sample was supplemented with vehicle control (HBS for the abxicimab, ACT017, and D-dimer, dimethyl sulfoxide for atopaxar) or the inhibitor (20 µg/mL abxicimab, 23 500 nmol/L atopaxar, 24 100 µg/mL ACT017, 25 30 µg/mL D-dimer 26 ). DiOC 6 (1 µmol/L) and Alexa 555-labeled fibrinogen (final concentration, 28 µg/mL) were added to the preparation for 15 minutes at 37°C. The sample was then perfused as in the reconstituted blood case (HCT, 0.4) at 372 µL/min through the device for 30 minutes. The second sample was then loaded with the drug or vehicle control and labeled for 15 minutes at 37°C and perfused through a second device under the same conditions. Images were captured with an inverted microscope (Olympus IX81, ×10 NA=0.3, ex/em 475/505 nm, 545/580 nm) every 10 seconds.
Phophatidylserine Labeling
Assays were run with reconstituted whole blood (HCT, 0.4) at Re=10. After 25 minutes of perfusion, flow was stopped, and the channel was rinsed 3× with Annexin V-binding buffer in the same direction of flow (blood inlet to blood outlet) using a pipette. The clot was then fixed by filling the channel with 2% glutaraldehyde in HBS for 10 minutes. The channel was then rinsed with the Annexin V-binding buffer and then filled with the Annexin V label mixed 1:1 with the binding buffer. The sample was incubated in the dark at room temperature for 45 minutes and then rinsed with Annexin V-binding buffer and imaged by confocal microscopy.
Image Quantification
Thrombus areas were measured by thresholding the overlay of platelet and fibrin(ogen) images using ImageJ (National Institutes of Health, Bethesda, MD). Integrated fluorescence of platelet accumulation was measured using ImageJ, and the average grayscale pixel brightness normalized by the maximum (4096 for a 16-bit TIFF).
Statistical Analysis
Data were determined normally distributed by the Anderson-Darling test. Statistical differences were measured using a Student t test or Mann-Whitney U test (for data sets that failed the Anderson-Darling test) for pairs and 1-way ANOVA for groups followed by a post hoc Tukey honestly significant difference procedure to compare pairs in MATLAB (R2016b, MathWorks, Natick, MA).
Results
Design and Characterization of Model Venous Valves
The flow through human venous valves depends on vessel size and body position. For example, in the common femoral vein, mean peak velocities ranged from 37.3 cm/s in supine leg up position to 1.3 cm/s in a sitting position. 27 At this scale, a prohibitive volume of blood would be required for observing thrombus formation in a single pass device. Therefore, we used a scaling approach to develop a model vein and venous valve with dimensional similarity to human venous valves. 28 The vessel stenosis ratio-vessel diameter:distance between valve leaflets-is the primary geometric ratio that dictates flow in an expansion. This ratio is ≈3:1 in the human greater saphenous vein and superficial femoral vein. 16, 29 In the scaled model, we use a 450-µm wide channel as the vessel and a 150-µm wide channel as the stenosis to achieve a 3:1 stenosis ratio. Previous studies have examined hemodynamics in a sudden expansion or stenosis to model arteriosclerotic geometries 30, 31 ; however, the existence of a valve sinus distal to the expansion created by the valve leaflets likely influences the flow field in large veins. To model the valve sinus, we fabricated devices with undercut angles of 90°, 120°, 135°, or 150° ( Figure 1A ).
We refer to the area near the opening of the valve sinus, the valve cusp, and the deeper regions as the valve pocket. The Re in veins can vary from 1 to 600 although in large human veins is typically Re >100. 27, 32, 33 The Re is a dimensionless quantity that characterizes the relative importance of inertial forces to viscous forces. To avoid shear-induced platelet activation, 34 we limited ourselves to Re=1 to 25, which is comparable to reports in fixed canine valves.
14 In flows with Re >1, inertial forces dominate. For sufficiently high Re, flow separation arises because of a counter acting pressure gradient against the direction of flow immediately downstream of the sudden expansion ( Figure 1B) . Fluid far from the wall has more inertia and is able to overcome this pressure gradient and continue downstream, but viscous forces acting on fluid in the near wall region reduce the inertia so that it cannot overcome the pressure gradient, causing recirculation. This flow separation is characterized by detachment and reattachment points ( Figure 1C) , as well as regions of low wall shear rates that are favorable for fibrin deposition. The area of the valve pocket with a wall shear rate <50/s, which can support fibrin deposition in the absence of blood cells, 35 depends on the Re and, more strongly, the undercut angle as predicted by simulations ( Figure 1D ). Above Re of 10, which is characteristic of large veins, 29 the low shear rate area was independent of Re. This suggests that valve geometry, more than blood flow, dictates flow in the valve pocket.
To visualize the flow field in the absence of blood cells, we perfused suspensions of 3 µm fluorescent particles through the scaled model and measured their streaklines (Figure 2A) . At Re=1 and all angles, we observe a particle free region in the valve pocket as indicated by the dark zones where few fluorescent particles were observed over a 1-hour experiment. Those particles that entered the corners of these zones had little apparent convective velocity, suggesting no or a small circulating flow. At Re=10, we observed flow separation and the entrainment of particles in a primary vortex at undercut angles of 135° and 150° as indicated by particle streaklines that move countercurrent to the bulk flow. At Re=25, we observed particle accumulation in the primary vortex at all angles except for 90°. The reattachment length as defined in Figure 1C 
RBC Enrich the Valve Pocket With Platelets and Platelet Sized Particles
In the presence of RBC, we observed enhanced entrainment of fluorescent particles in the valve pocket for HCT of 0.2, 0.4, and 0.6 compared with experiments with no RBC ( Figure 2B ; Figure IV and Video I in the online-only Data Supplement). To provide a faithful comparison of the flow field independent of HCT, the Re rather than the flow rate were matched. An HCTdependent function for the viscosity was used to calculate Re (see Methods). 22 The reattachment length remained constant across matched Re for all HCT values, confirming that this is the appropriate scaling parameter ( Figure III in the online-only Data Supplement). In experiments where TF was immobilized in the valve pocket, the rate of platelet accumulation in the valve pocket was enhanced by ≈3-fold in reconstituted blood with an HCT of 0.4 compared with PRP (P=0.0213; Figure V in the online-only Data Supplement). In the 135° and 150° expansion angles, RBC also entered and became trapped in the valve pocket and the initial fibrin gel (Movie II in the online-only Data Supplement). These data show that RBC enhance the transport of platelet and platelet sized particles into the valve pocket.
Low Flow Regions in Model Valve Pockets Support Initial Fibrin Formation and Thrombus Growth
To determine the influence of undercut angle on the initiation of thrombus formation, PRP and reconstituted blood (PRP with RBC) were perfused at a Re of 10 through devices with undercut angles of 90° and 150°, where TF was immobilized on the surface of the model valve sinus ( Figure 3A ; Movies III and IV in the online-only Data Supplement). Fibrin deposition occurred in the lowest flow regions within 10 minutes for the 90° undercut angle and within 5 minutes for the 150° undercut angle. Initial fibrin deposition coincided with areas with a wall shear rate of <50/s ( Figure 3B ). For a 90° undercut angle, simulations predict a single vortex ( Figure 3C ), and only moderate fibrin formation was observed followed by platelet accumulation ( Figure 3A) . For a 150° undercut angle, a fibrin gel first fills the area coinciding with the predicted secondary vortex ( Figure 3C ), followed by platelet adhesion and aggregation which then support spatial propagation of the thrombus that ultimately grows out of the valve pocket ( Figure 3A) . These data suggest that the valve pocket geometry and in particular regions of very low flow protect coagulation and fibrin polymerization reactions and support initial platelet accumulation.
Platelets and RBC Are Necessary for Thrombus Propagation Out of the Valve Sinus
To determine the roles of platelets and RBC on thrombus growth in our model valve sinus, NPP, PRP, NPP containing RBC, and reconstituted blood (PRP with RBC) were perfused at an Re of 10 through devices with a 150° undercut angle ( Figure 4A ). For NPP, fibrin formed within 3 to 5 minutes in the valve pocket region with the lowest shear rate as described above but did not extend beyond the area defined by the initial secondary vortex ( Figure 4A ; Movie IV in the online-only Data Supplement). Note the concave interface of the fibrin gel mirrors the interface between the primary and secondary vortex from particle streaklines ( Figure 2 ) and simulations ( Figure 3) . Fibrin fibers were densest at the interface, suggesting an accumulation of coagulation proteins and fibrin(ogen) transported by flow into the primary vortex. The interface moved slowly; it extended just 50 µm over 30 minutes. Control experiments in the absence of immobilized TF showed fibrin deposition only in the deepest part of the valve pocket and only after 30 minutes of perfusion (Video V in the online-only Data Supplement).
PRP yielded similar sized thrombi as NPP ( Figure 4A ; Movie IV in the online-only Data Supplement). Platelets tend to accumulate near the detachment point at the valve cusp and to a lesser extent at the fibrin gel interface within the primary vortex. In regions near adhered platelets, the fibrin gel grows denser with time relative to gels formed with NPP, possibly because of platelet retraction or additional coagulation. However, thrombus size is similar to that of NPP after 30 minutes ( Figure 4B ). Thus, platelets in the absence of RBC do not support the propagation of thrombi beyond the low flow region defined by the secondary vortex.
NPP with suspended RBC at HCT of 0.4 and 0.6 yielded fibrin deposition that was also limited to the valve pocket. Here, the morphology of the fibrin gel is different because RBC were incorporated in the fibrin gel ( Figure 4A ). However, these RBC did not support additional thrombus growth beyond what was observed for NPP after 30 minutes ( Figure 4B ; Movie IV in the online-only Data Supplement). In control experiments without TF, RBC became trapped in the valve pocket, but no fibrin fibers were observed (Movie V in the online-only Data Supplement). It does not seem that RBC alone support additional coagulation that results in observable enhancement of thrombus growth compared with plasma alone. The shear-dependent viscosity of RBC suspended in NPP or autologous plasma was statistically similar (Figure VI in the online-only Data Supplement), suggesting that RBC agglutination was not enhanced in NPP.
Reconstituted blood containing both platelets and RBC supports robust thrombus growth out of the valve pocket and into the bulk flow. These thrombi were roughly double the size of those formed with NPP, PRP, and NPP with RBC at 30 minutes ( Figure 4B ; Movie IV in the online-only Data Supplement). Compared with PRP, experiments with reconstituted blood show that platelets in the primary vortex adhere in a dense layer to the initial fibrin gel formed in the valve pocket, followed by the rapid formation of a thrombus that extends past the primary vortex ( Figure 4A ; Movie IV in the online-only Data Supplement). The thrombi grew beyond the field-of-view during some experiments, so exact thrombus sizes were not available for all assays. HCT of 0.4 and 0.6 yielded similar thrombus growth rates and sizes ( Figure 4B ). Alternating platelet-and RBC-rich zones are apparent as the thrombus penetrated into the main channel (Movies II and IV in the online-only Data Supplement).
Reconstituted blood (RBC, platelets, and plasma) and whole blood yield similar results in terms of thrombus area and growth rate ( Figure VII in the online-only Data Supplement). These data suggest that leukocytes do not play a significant role in this model of thrombus propagation.
Platelets Adhered to Fibrin in the Valve Sinus Can Become Procoagulant
In both PRP and reconstituted blood experiments, we observed regions in the valve pocket where the DiOC 6 dye, which labels the mitochondrial membrane, began to fade at around 10 minutes after initial adhesion (Figure 5A and 5B; Movie IV in the online-only Data Supplement). We hypothesized that this was indicative of mitochondrial depolarization because of platelet activation and would lead to subsequent exposure to phosphatidylserine. 33 To test this hypothesis, we performed experiments with reconstituted blood (HCT, 0.4) at Re of 10 for 25 minutes, fixed the thrombi, and then used annexin V to label phosphatidylserine ( Figure 5C ). We found that annexin V-positive platelets were localized in dense fibrin networks near the fluid-thrombus interface and in large platelet aggregates. Platelets that lost their DiOC 6 signal during the perfusion experiment were found to be annexin V positive after fixation.
Platelets Aggregation in the Valve Sinus Is Supported by GPVI Signaling
Finally, to determine what interactions mediate activation of platelets adhered to fibrin, we conducted experiments with a series of platelet receptor inhibitors. Whole blood was treated with the α IIb β 3 inhibitor abciximab, the PAR1 (protease-activated receptor 1) inhibitor atopaxar, an anti-glycoprotein VI (GPVI) humanized Fab fragment ACT017, 36 or D-dimer that binds to GPVI. 26, 37 Blood was perfused at Re=10 through TF-coated devices with a 150° undercut angle. In all cases, an initial fibrin gel was formed as in reconstituted blood and plasma conditions. Abciximab abrogates platelet buildup beyond the first layer of platelets on the fibrin gel ( Figure 6 ). Atopaxar, a PAR1 inhibitor, showed modest but not significant differences in thrombus area compared with vehicle controls. Treatment with ACT017 and D-dimer did reduce total thrombus area in a spatially dependent manner; platelets still aggregate around the corner proximal to the expansion, but their accumulation adjacent to fibrin in the valve pocket or on the distal wall was diminished.
Discussion
In this study, we designed a model of TF-initiated VT that captures some of the important hemodynamic features of human venous valves, specifically, primary and secondary vortices and flow separation in an expansion geometry with an undercut. An initial fibrin gel formed in the low flow region of the secondary vortex in the deepest part of the valve pocket independent of blood cells. Both RBC and platelets were necessary for thrombus growth beyond the valve pocket. Platelets support thrombus growth beyond the initial fibrin gel by adhering, activating, and for at least a subpopulation, becoming procoagulant. These results suggest a biophysical mechanism of thrombus propagation that depends on both flow-enhanced platelet-RBC interactions upstream of a valve and low flow niches that protect coagulation reactions and support platelet adhesion to fibrin (Figure VIII in the onlineonly Data Supplement).
The initiation of coagulation and fibrin polymerization require protection from dilution by blood flow. 38 Computational models of VT suggest that a threshold concentration of TF must first accumulate on the valve wall before coagulation can initiate. 39 Here, we have skipped the steps leading up the accumulation of TF and started with a surface TF concentration capable of initiating coagulation. Previous studies found that even at high thrombin or TF concentrations, fibrin can only form at wall shear rates <100/s in the absence of adhered blood cells. 6, 35 That is consistent with observations in this study, where the low flow region defined by shear rates of <50/s in the valve pocket was the nidus for fibrin deposition. The size of this initial fibrin gel was dictated by the degree of undercut, more so than the Re.
RBC promote thrombus propagation by enhancing the transport of platelets into the valve pocket at a sufficient rate to support coagulation beyond the TF-coated valve. Based on studies in nonbiological dense suspensions in sudden expansions where margination occurs because of size exclusion effects, 40 we would expect this is because of platelet margination upstream from the expansion point, rather than increased collision frequency within the vortices. Elevated hematocrit is correlated with increased risk for VT. 41 In our model, we did not observe a significant difference in thrombus growth between hematocrits of 0.4 and 0.6. However, these experiments were conducted at a constant Re to provide faithful comparison of the hemodynamics while the cardiovascular system is likely regulated by other parameters like oxygen demand.
The procoagulant activity of RBC reported by others 42 was not sufficient in these studies to initiate fibrin deposition in the absence of TF nor to enhance it in absence of platelets. This observation is consistent with in vivo, in vitro, and in silico models of arterial thrombosis where the primary influence of an elevated hematocrit is to promote plateletdependent thrombus growth rather than coagulation. 43 RBC do contribute to the architecture and mechanics of venous thrombi; they are retained in fibrin-rich thrombi via factor XIII-dependent fibrin α-chain cross-linking 44, 45 and organize to form densely packed structures following platelet-mediated contraction 46 that could limit transport of coagulation products into and out of the growing thrombus. RBC can also adhere to activated platelets and fibrin at low shear rates, such as those found in vortices. 47 Platelet adhesion to fibrin and subsequent activation through GPVI are essential in this model for thrombus propagation. Platelets adhered to fibrin along the entire periphery of the primary vortex and formed a platelet-rich layer reminiscent of the laminate structure of thrombi formed in the venous valves of humans. 13 Some platelets within this layer become procoagulant, supporting the formation of an adjacent fibrin-rich thrombus that penetrates from the valve sinus into the bulk flow. In agreement with previous studies, 48, 49 some platelets adhered to fibrin exposed phosphatidylserine. Treatments with the GPVI blocking Fab fragment (ACT017) or D-dimer reduced thrombus growth. This is consistent with reports that GPVI can bind to the D-domain on fibrin(ogen) although whether the monomer or dimer of GPVI governs this interaction is a subject of debate. 26, 37 Importantly, D-dimer may also limit thrombus growth by inhibiting fibrin polymerization and α IIb β 3 interactions. Even when inhibiting GPVI, there was platelet accumulation around the corner that defines the valve cusp. Platelet accumulation in this region is possibly driven by activationindependent aggregation as previously shown downstream of stenotic geometries. There is not an established relationship between GPVI and VT risk in humans. However, reduced platelet responsiveness to GPVI agonists, which is presumed to be a consequence of continuous activation, is associated with a higher risk of venous thromboembolism. 50 Our findings that platelets are necessary for thrombus propagation in an in vitro model using human blood are consistent with the murine IVC flow restriction model. 11 In our model, platelets do not play a significant role in the initiation of a thrombus, which is consistent with a lack of platelets at the thrombus nidus in vivo (the valve pocket in our model), but presence in successive layers (the valve cusp and beyond). 51 In some animal models of VT, platelets play an essential role in early events thrombus growth 11, 52 although it is difficult to delineate initiation from propagation in these models.
There are several limitations of this study. First, because the model valve leaflet is fixed, we do not capture the hemodynamics associated with valve opening and closing. This is an approach similar to other in vitro and computational studies of VT, 12, 39 and we argue it is a relevant model for valvular stasis. Second, to use a nonprohibitive volume of human blood and avoid shear-induced platelet activation, we used scaling arguments to create a small version of a human venous valve. This model captures the essential hemodynamics, but the time scale for thrombus propagation is naturally shortened because of the smaller length scales. Third, leukocytes and specifically neutrophils and neutrophil extracellular traps may play a role in the initiation of VT. 11, 52, 53 These mechanisms were not explicitly studied here; however, the presence of leukocytes in whole-blood experiments did not seem to influence thrombus growth or size compared with reconstituted blood without leukocytes. Fourth, the surface-bound anticoagulants thrombomodulin and heparin sulfate are not present in this model. Computational studies suggest that coagulation can be initiated in the presence of these anticoagulants with a sufficient quantity of TF.
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Figure 6. Thrombus growth is driven by platelet activation through glycoprotein VI (GPVI). Representative images of thrombus formation with whole blood for vehicle control (A) and treatments with atopaxar (B), D-dimer (C), anti-GPVI antibody ACT017 (D), and abciximab (E) after 30-min perfusion. Scale bar, 100 µm. F, Thrombus areas for vehicle controls and each treatment. The means (n=6) and standard error are plotted. Statistical differences between vehicle and inhibitors were measured by ANOVA followed by Tukey test for multiple comparisons.
